200 related articles for article (PubMed ID: 11642503)
1. Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
Kashyap A; Snowden J
J Rheumatol Suppl; 2001 Oct; 64():39-41. PubMed ID: 11642503
[TBL] [Abstract][Full Text] [Related]
2. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
3. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR.
Snowden JA; Passweg J; Moore JJ; Milliken S; Cannell P; Van Laar J; Verburg R; Szer J; Taylor K; Joske D; Rule S; Bingham SJ; Emery P; Burt RK; Lowenthal RM; Durez P; McKendry RJ; Pavletic SZ; Espigado I; Jantunen E; Kashyap A; Rabusin M; Brooks P; Bredeson C; Tyndall A
J Rheumatol; 2004 Mar; 31(3):482-8. PubMed ID: 14994391
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.
Oyama Y; Traynor AE; Barr W; Burt RK
Bone Marrow Transplant; 2003 Aug; 32 Suppl 1():S81-3. PubMed ID: 12931250
[TBL] [Abstract][Full Text] [Related]
5. Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
Kang HJ; Shin HY; Choi HS; Han KS; Ahn HS
Bone Marrow Transplant; 2004 Mar; 33(5):471-6. PubMed ID: 14716339
[TBL] [Abstract][Full Text] [Related]
6. Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
Loh SM; Ratnagopal P; Tan HC; Goh YT; Koh BC; Koh LP; Linn YC; Hwang WY
Int J Hematol; 2006 May; 83(4):368-9. PubMed ID: 16757442
[No Abstract] [Full Text] [Related]
7. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
[TBL] [Abstract][Full Text] [Related]
8. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
9. Future strategies in hematopoietic stem cell transplantation for rheumatoid arthritis.
Burt RK; Barr W; Oyama Y; Traynor A; Slavin S
J Rheumatol Suppl; 2001 Oct; 64():42-8. PubMed ID: 11642504
[TBL] [Abstract][Full Text] [Related]
10. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
11. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Leger C; Sabloff M; McDiarmid S; Bence-Bruckler I; Atkins H; Bredeson C; Zhang H; Huebsch L
Ann Hematol; 2006 Oct; 85(10):723-9. PubMed ID: 16832675
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
[TBL] [Abstract][Full Text] [Related]
13. Immunomagnetic selection of CD34(+) cells carried out in cryopreserved cell concentrates from a paediatric patient affected with non-Hodgkin lymphoma.
Zinno F; Landi F; Aureli V; Cometa AM; Scerpa MC; Caniglia M; Pinto RM; Rana I; Balduino G; Miele MJ; Isacchi G
Transfus Med; 2010 Aug; 20(4):283-6. PubMed ID: 20136780
[No Abstract] [Full Text] [Related]
14. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Buser AS; Stern M; Bucher C; Arber C; Heim D; Halter J; Meyer-Monard S; Stussi G; Lohri A; Ghielmini M; Tichelli A; Passweg JR; Gratwohl A
Bone Marrow Transplant; 2007 Mar; 39(6):335-40. PubMed ID: 17342158
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.
Bishton MJ; Haynes AP
Br J Haematol; 2007 Jan; 136(1):111-3. PubMed ID: 17116129
[TBL] [Abstract][Full Text] [Related]
16. Intensive immunosuppression and autologous stem cell transplantation for patients with severe rheumatoid arthritis: the Leiden experience.
van Laar JM; Verburg RJ; Fibbe WE; Breedveld FC
J Rheumatol Suppl; 2001 Oct; 64():25-7. PubMed ID: 11642499
[TBL] [Abstract][Full Text] [Related]
17. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
18. FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Ashizawa M; Kako S; Wada H; Sakamoto K; Sato M; Terasako K; Kimura S; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Kanda Y
Hematol Oncol; 2012 Mar; 30(1):50-2. PubMed ID: 21574175
[No Abstract] [Full Text] [Related]
19. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
20. High dose therapy and autologous hemopoietic stem cell transplantation in rheumatoid arthritis--the feasibility of phase III trials.
Snowden J
J Rheumatol Suppl; 2001 Oct; 64():55-9. PubMed ID: 11642507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
